Mesoblast Limited (MESO) Receives Daily News Impact Rating of 0.10
Media coverage about Mesoblast Limited (NASDAQ:MESO) has been trending somewhat positive this week, according to Accern. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mesoblast Limited earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.9500409501796 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the headlines that may have effected Accern’s rankings:
- Research Analysts Offer Predictions for Mesoblast Limited’s Q1 2019 Earnings (MESO) (americanbankingnews.com)
- Market Data Forecast Releases New Report on North America Regenerative Medicines Market by 2021 (reports.pr-inside.com)
- Global Diabetic Nephropathy Industry Report with Analysis of Market Share by Product Types, Applications and Regions (emailwire.com)
- Regenerative Therapies Market is projected to US$ 18,429.8 Mn by 2022 (medgadget.com)
- Mesoblast Becomes Oversold (MESO) (thestreet.com)
Mesoblast Limited (MESO) traded up 0.74% during midday trading on Friday, hitting $5.48. The stock had a trading volume of 10,171 shares. The company’s market cap is $465.49 million. The stock’s 50 day moving average price is $6.46 and its 200-day moving average price is $8.22. Mesoblast Limited has a 52 week low of $4.01 and a 52 week high of $12.50.
A number of brokerages have commented on MESO. Maxim Group restated a “buy” rating and issued a $14.00 target price on shares of Mesoblast Limited in a research note on Tuesday. ValuEngine downgraded Mesoblast Limited from a “hold” rating to a “sell” rating in a research note on Friday, September 15th. CIBC began coverage on Mesoblast Limited in a research note on Thursday, August 31st. They issued an “outperform” rating and a $16.00 target price for the company. Oppenheimer Holdings, Inc. began coverage on Mesoblast Limited in a research note on Thursday, August 31st. They issued an “outperform” rating and a $16.00 target price for the company. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $20.00 target price on shares of Mesoblast Limited in a research note on Wednesday, August 30th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $13.64.
TRADEMARK VIOLATION WARNING: This report was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/09/30/mesoblast-limited-meso-receives-daily-news-impact-rating-of-0-10.html.
Mesoblast Limited Company Profile
Receive News & Stock Ratings for Mesoblast Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Limited and related stocks with our FREE daily email newsletter.